LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.15 4.55

Buy Sell

Overview

Share price change

24h

Current

Min

1.13

Max

1.16

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+334.78% upside

Market Stats
By TradingEconomics
Market Cap	-2.3M 123M
Previous open	-3.4
Previous close	1.15

News Sentiment

By Acuity

40%

60%

115 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 gru 2025, 22:53 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 gru 2025, 00:04 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 gru 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 gru 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 gru 2025, 22:38 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 gru 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 gru 2025, 22:01 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 gru 2025, 22:01 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 gru 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Acquire Remaining 64% of Alta Copper

14 gru 2025, 17:00 UTC

Earnings

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 gru 2025, 08:30 UTC

Acquisitions, Mergers, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 gru 2025, 16:48 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 gru 2025, 08:00 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 gru 2025, 07:00 UTC

Acquisitions, Mergers, Takeovers

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 gru 2025, 00:24 UTC

Acquisitions, Mergers, Takeovers

Want a Piece Of SpaceX? -- Barrons.com

12 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 gru 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 gru 2025, 22:32 UTC

Earnings

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 gru 2025, 20:45 UTC

Earnings

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 gru 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 gru 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 gru 2025, 19:23 UTC

Earnings

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 gru 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 gru 2025, 18:33 UTC

Acquisitions, Mergers, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 gru 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 gru 2025, 17:49 UTC

Earnings

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 gru 2025, 17:34 UTC

Acquisitions, Mergers, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

334.78% upside

12 Months Forecast

Average 5 USD 334.78%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

115 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.